[go: up one dir, main page]

HK1008731A1 - Antibody for the treatment of insulin dependent diabetes - Google Patents

Antibody for the treatment of insulin dependent diabetes Download PDF

Info

Publication number
HK1008731A1
HK1008731A1 HK98108899A HK98108899A HK1008731A1 HK 1008731 A1 HK1008731 A1 HK 1008731A1 HK 98108899 A HK98108899 A HK 98108899A HK 98108899 A HK98108899 A HK 98108899A HK 1008731 A1 HK1008731 A1 HK 1008731A1
Authority
HK
Hong Kong
Prior art keywords
vla4
antibody
diabetes
cells
use according
Prior art date
Application number
HK98108899A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1008731B (en
Inventor
C. Burkly Linda
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21848497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1008731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of HK1008731B publication Critical patent/HK1008731B/en
Publication of HK1008731A1 publication Critical patent/HK1008731A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK98108899A 1993-02-09 1994-02-09 Antibody for the treatment of insulin dependent diabetes HK1008731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2933093A 1993-02-09 1993-02-09
US29330 1993-02-09
PCT/US1994/001456 WO1994017828A2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes

Publications (2)

Publication Number Publication Date
HK1008731B HK1008731B (en) 1999-05-14
HK1008731A1 true HK1008731A1 (en) 1999-05-14

Family

ID=21848497

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98108899A HK1008731A1 (en) 1993-02-09 1994-02-09 Antibody for the treatment of insulin dependent diabetes

Country Status (13)

Country Link
US (2) US5888507A (el)
EP (1) EP0682529B2 (el)
JP (1) JP3593343B2 (el)
AT (1) ATE161730T1 (el)
AU (1) AU687790B2 (el)
CA (1) CA2155303C (el)
DE (1) DE69407758T3 (el)
DK (1) DK0682529T4 (el)
ES (1) ES2114183T5 (el)
GR (1) GR3026531T3 (el)
HK (1) HK1008731A1 (el)
NZ (1) NZ262615A (el)
WO (1) WO1994017828A2 (el)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
EP0678122B1 (en) * 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
CA2155303C (en) * 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
BR9808934A (pt) * 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CN1236815C (zh) 1998-09-14 2006-01-18 德克萨斯州立大学董事会 整联蛋白拮抗剂在制备治疗多发性骨髓瘤和骨髓瘤诱发的骨吸收的药物中的应用
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6110109A (en) * 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
WO2000064474A1 (en) 1999-04-22 2000-11-02 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
ES2263485T3 (es) * 1999-09-14 2006-12-16 Biogen Idec Ma Inc. Terapia para insuficiencia renal cronica utilizando uno o mas angtagonistas de integrinas.
IL149933A0 (en) 1999-12-06 2002-11-10 Gen Hospital Corp Pancreatic stem cells and their use in transplantation
DK2140881T3 (da) 1999-12-16 2013-05-06 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ATE471344T1 (de) 2001-04-13 2010-07-15 Biogen Idec Inc Antikörper gegen vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
EP2484381A1 (en) 2003-01-24 2012-08-08 Elan Pharmaceuticals Inc. Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1827491A4 (en) 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
US20090169477A1 (en) * 2004-12-03 2009-07-02 Michael Panzara Delaying or preventing onset of multiple sclerosis
US8124350B2 (en) 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
AU2007267579B2 (en) 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
CA2690382A1 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
EP3808348A1 (en) 2007-09-14 2021-04-21 Biogen MA Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
JP2013525260A (ja) * 2009-04-17 2013-06-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 急性骨髄性白血病を治療するための組成物および方法
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
JP2013507618A (ja) 2009-10-11 2013-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｖｌａ‐４関連アッセイ
EP3202789B1 (en) 2010-04-16 2020-05-06 Biogen MA Inc. Anti-vla-4 antibodies
AU2011323820A1 (en) 2010-10-25 2013-05-23 Biogen Ma Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2814468B1 (en) 2012-02-16 2019-06-19 Santarus, Inc. Anti-vla1 (cd49a) antibody pharmaceutical compositions
LT2828284T (lt) 2012-03-20 2019-08-26 Biogen Ma Inc. Jcv neutralizuonatys antikūnai
WO2013158969A1 (en) 2012-04-20 2013-10-24 Biogen Idec Ma Inc. Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
HK1211361A1 (en) 2012-08-13 2016-05-20 Biogen Ma Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
HK1213794A1 (zh) 2012-10-09 2016-07-15 Biogen Ma Inc. 聯合治療及用於治療脫髓鞘病症的用途
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
CA3133072A1 (en) 2019-03-11 2020-09-17 Biogen Ma Inc. Pharmaceutical compositions containing anti-lingo-1 antibodies
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
ATE142505T1 (de) * 1988-11-14 1996-09-15 Brigham & Womens Hospital Antikörper, spezifisch gegen elam-1 sowie deren verwendung
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
IL113261A (en) † 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
ES2103468T3 (es) * 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
AU689454B2 (en) * 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
EP0678122B1 (en) * 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
CA2155303C (en) * 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
HU220799B1 (hu) * 1994-01-25 2002-05-28 Elan Pharmaceuticals, Inc. Humanizált antitestek VLA-4 leukocita adhéziós molekula ellen

Also Published As

Publication number Publication date
CA2155303A1 (en) 1994-08-18
JP3593343B2 (ja) 2004-11-24
GR3026531T3 (en) 1998-07-31
CA2155303C (en) 2010-04-20
ES2114183T3 (es) 1998-05-16
WO1994017828A3 (en) 1994-10-13
AU6237994A (en) 1994-08-29
EP0682529B2 (en) 2005-12-28
JPH08508719A (ja) 1996-09-17
EP0682529A1 (en) 1995-11-22
US5888507A (en) 1999-03-30
DE69407758T2 (de) 1998-08-27
DK0682529T4 (da) 2006-05-15
AU687790B2 (en) 1998-03-05
EP0682529B1 (en) 1998-01-07
DE69407758D1 (de) 1998-02-12
NZ262615A (en) 1996-02-27
ES2114183T5 (es) 2006-06-16
DE69407758T3 (de) 2007-05-24
DK0682529T3 (da) 1998-09-07
WO1994017828A2 (en) 1994-08-18
ATE161730T1 (de) 1998-01-15
US20050208053A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EP0682529B1 (en) Antibody for the treatment of insulin dependent diabetes
HK1008731B (en) Antibody for the treatment of insulin dependent diabetes
US7211252B2 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
JP2013166765A (ja) ステロイド節約剤およびそれを使用する方法
EP1003552B1 (en) LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
EP0606518B1 (en) Intercellular adhesion molecules and their binding ligands
US20100183599A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
HUP0202568A2 (hu) VLA-1 elleni blokkoló hatású monoklonális antitest és alkalmazása gyulladásos rendellenességek kezelésére
US20140234299A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
EP0786255A1 (en) Methods of improving allograft or xenograft tolerance by administration of an LFA-3 or CD2 binding protein
AU727187B2 (en) Treatment for insulin dependent diabetes
Behrend Immune-adhesion molecules in the prevention of allograft rejection and reperfusion injury
EP2267029B1 (en) Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
AU2011213878B2 (en) Steroid sparing agents and methods of using same
US20020041874A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
JP4808841B2 (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
CA2361637A1 (en) Porcine b7-1 and antibodies thereto
HK1112193A (en) A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
HK1038313B (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
HK1025738B (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation

Legal Events

Date Code Title Description
PF Patent in force
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130209